PE20071228A1 - Compuestos derivados de purina como activadores del receptor de adenosina a2a - Google Patents

Compuestos derivados de purina como activadores del receptor de adenosina a2a

Info

Publication number
PE20071228A1
PE20071228A1 PE2007000481A PE2007000481A PE20071228A1 PE 20071228 A1 PE20071228 A1 PE 20071228A1 PE 2007000481 A PE2007000481 A PE 2007000481A PE 2007000481 A PE2007000481 A PE 2007000481A PE 20071228 A1 PE20071228 A1 PE 20071228A1
Authority
PE
Peru
Prior art keywords
alkyl
hydroxy
amino
adenosine
purine
Prior art date
Application number
PE2007000481A
Other languages
English (en)
Inventor
Robin Alec Fairhurst
Roger John Taylor
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20071228A1 publication Critical patent/PE20071228A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE PURINA DE FORMULA (I) DONDE U1 Y U2 SON CADA UNO CH2 U O; R1a Y R1b SON CADA UNO HETEROCICLO DE 3 A 12 MIEMBROS QUE CONTIENE DE 1 A 4 ATOMOS DE N, HIDROXIALQUILO(C1-C8), CH2-O-ALQUILO(C1-C8), ENTRE OTROS; R2a Y R2b SON CADA UNO ALQUILO(C1-C8) OPCIONALMENTE SUSTITUIDO CON OH, HALOGENO, ENTRE OTROS SUSTITUYENTES, O-ALQUILO(C1-C8), ENTRE OTROS; X1 Y X2 SON CADA UNO ALQUILO(C1-C8), ALQUENILO(C2-C8), ALQUINILO(C2-C8), UN ENLACE, ENTRE OTROS; L ES -NR5-C(=NR5)-NR5, -NR5-Y-NR5-, ENTRE OTROS, DONDE Y ES HETEROCICLO DE 3 A 12 MIEMBROS QUE CONTIENE N, ENTRE OTROS; R5 ES H, CN, ALQUILO(C1-C8) O ARILO(C6-C10). SON COMPUESTOS PREFERIDOS: 1,3-BIS-{(1S,2R,3S,4R)-1-[6-(2,2-DIFENIL-ETIL-AMINO)-9-(4-(2-HIDROXI-ACETAMIDO)-2,3-DIHIDROXI-CICLOPENTIL)-9H-PURIN-2-IL]-1H-PIRAZOL-4-IL}-UREA, 1,3-BIS-{1-[9-[(1R,2S,3R,4S)-2,3-DIHIDROXI-4-(2-HIDROXI-ACETIL-AMINO)-CICLOPENTIL]-6-((S)-1-HIDROXI-METIL-2-FENIL-ETIL-AMINO)-9H-PURIN-2-IL]-1H-PIRAZOL-4-IL}-UREA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS ACTIVAN EL RECEPTOR DE ADENOSINA A2A SIENDO UTILES EN EL TRATAMIENTO DE ENFERMEDAD OBSTRUCTIVA CRONICA PULMONAR, ENFISEMA, ASMA, PSORIASIS, VITILIGO
PE2007000481A 2006-04-21 2007-04-19 Compuestos derivados de purina como activadores del receptor de adenosina a2a PE20071228A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0607950.3A GB0607950D0 (en) 2006-04-21 2006-04-21 Organic compounds

Publications (1)

Publication Number Publication Date
PE20071228A1 true PE20071228A1 (es) 2008-01-24

Family

ID=36581047

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000481A PE20071228A1 (es) 2006-04-21 2007-04-19 Compuestos derivados de purina como activadores del receptor de adenosina a2a

Country Status (32)

Country Link
US (1) US8193164B2 (es)
EP (1) EP2018388B9 (es)
JP (1) JP2009534341A (es)
KR (1) KR20080112399A (es)
CN (1) CN101437829B (es)
AR (1) AR060606A1 (es)
AT (1) ATE502040T1 (es)
AU (1) AU2007241347A1 (es)
CA (1) CA2648037A1 (es)
CL (1) CL2007001132A1 (es)
CR (1) CR10328A (es)
CY (1) CY1111568T1 (es)
DE (1) DE602007013203D1 (es)
DK (1) DK2018388T3 (es)
EC (1) ECSP088837A (es)
ES (1) ES2363255T3 (es)
GB (1) GB0607950D0 (es)
GT (1) GT200800218A (es)
HR (1) HRP20110445T1 (es)
IL (1) IL194398A0 (es)
MA (1) MA30404B1 (es)
MX (1) MX2008013398A (es)
NO (1) NO20084456L (es)
PE (1) PE20071228A1 (es)
PL (1) PL2018388T3 (es)
PT (1) PT2018388E (es)
RU (1) RU2008145715A (es)
SI (1) SI2018388T1 (es)
TN (1) TNSN08409A1 (es)
TW (1) TW200813074A (es)
WO (1) WO2007121924A2 (es)
ZA (1) ZA200808103B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
US9512125B2 (en) 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
KR20120051760A (ko) 2006-04-04 2012-05-22 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 키나제 길항물질
PL2322525T3 (pl) 2006-04-21 2014-03-31 Novartis Ag Pochodne puryny do zastosowania jako agoniści receptora adenozyny A<sub>2A</sub>
GB0607950D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607944D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
EP1889846A1 (en) 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
EP1903044A1 (en) 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
KR20090087054A (ko) * 2006-11-10 2009-08-14 노파르티스 아게 시클로펜텐 디올 모노아세테이트 유도체
US20110160232A1 (en) 2007-10-04 2011-06-30 Pingda Ren Certain chemical entities and therapeutic uses thereof
MX2010004234A (es) * 2007-10-17 2010-04-30 Novartis Ag Derivados de purina como ligandos del receptor de adenosina a1.
US20090181934A1 (en) * 2007-10-17 2009-07-16 Novartis Ag Organic Compounds
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
MX2010007418A (es) 2008-01-04 2010-11-12 Intellikine Inc Ciertas entidades quimicas, composiciones y metodos.
JP5547099B2 (ja) 2008-03-14 2014-07-09 インテリカイン， エルエルシー キナーゼ阻害剤および使用方法
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
JP5788316B2 (ja) 2008-07-08 2015-09-30 インテリカイン， エルエルシー キナーゼインヒビターおよび使用方法
JP5731978B2 (ja) 2008-09-26 2015-06-10 インテリカイン， エルエルシー 複素環キナーゼ阻害剤
CA2740885C (en) 2008-10-16 2018-04-03 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
JP5789252B2 (ja) 2009-05-07 2015-10-07 インテリカイン， エルエルシー 複素環式化合物およびその使用
WO2011047384A2 (en) 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
US8604032B2 (en) 2010-05-21 2013-12-10 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
CN103298474B (zh) 2010-11-10 2016-06-29 无限药品股份有限公司 杂环化合物及其用途
WO2012097000A1 (en) 2011-01-10 2012-07-19 Pingda Ren Processes for preparing isoquinolinones and solid forms of isoquinolinones
AR085397A1 (es) 2011-02-23 2013-09-25 Intellikine Inc Combinacion de inhibidores de quinasa y sus usos
EP2734520B1 (en) 2011-07-19 2016-09-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP2734530A1 (en) 2011-07-19 2014-05-28 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA2846431A1 (en) 2011-08-29 2013-03-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
AU2012341028C1 (en) 2011-09-02 2017-10-19 Mount Sinai School Of Medicine Substituted pyrazolo[3,4-D]pyrimidines and uses thereof
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
CA2886240A1 (en) 2012-09-26 2014-04-03 The Regents Of The University Of California Modulation of ire1
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
DK3052485T3 (da) 2013-10-04 2021-10-11 Infinity Pharmaceuticals Inc Heterocykliske forbindelser og anvendelser deraf
SG11201607705XA (en) 2014-03-19 2016-10-28 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
WO2017048702A1 (en) 2015-09-14 2017-03-23 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US11147818B2 (en) 2016-06-24 2021-10-19 Infinity Pharmaceuticals, Inc. Combination therapies
US20200055883A1 (en) 2017-02-17 2020-02-20 Eisai R&D Management Co., Ltd. Cyclic di-nucleotides derivative for the treatment of cancer

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1528382A (en) * 1974-12-26 1978-10-11 Teijin Ltd Cyclopentene diols and acyl esters thereof and processes for their preparation
US4738954A (en) * 1985-11-06 1988-04-19 Warner-Lambert Company Novel N6 -substituted-5'-oxidized adenosine analogs
US4873360A (en) * 1986-07-10 1989-10-10 Board Of Governors Of Wayne State University Process for the preparation of cyclopentanoids and novel intermediates produced thereby
EP0267878A1 (en) 1986-11-14 1988-05-18 Ciba-Geigy Ag N9-cyclopentyl-substituted adenine derivatives
US4954504A (en) * 1986-11-14 1990-09-04 Ciba-Geigy Corporation N9 -cyclopentyl-substituted adenine derivatives having adenosine-2 receptor stimulating activity
JP2586897B2 (ja) 1987-03-09 1997-03-05 富士薬品工業株式会社 光学活性なシス−シクロペンテン−３，５−ジオ−ルモノエステルの製造法
DE69123974T2 (de) 1990-09-25 1997-05-07 Rhone-Poulenc Rorer International (Holdings) Inc., Greenville, Del. Verbindungen welche antihypertensive und antiischemische eigenschaften besitzen
IT1254915B (it) 1992-04-24 1995-10-11 Gloria Cristalli Derivati di adenosina ad attivita' a2 agonista
US5688774A (en) * 1993-07-13 1997-11-18 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
US5691188A (en) * 1994-02-14 1997-11-25 American Cyanamid Company Transformed yeast cells expressing heterologous G-protein coupled receptor
PT909270E (pt) * 1996-01-02 2002-11-29 Aventis Pharma Inc Processo para a preparacao de 2,4-dihidroxipiridina e de 2,4-dihidroxi-3-nitropiridina
US6376472B1 (en) * 1996-07-08 2002-04-23 Aventis Pharmaceuticals, Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
WO1998050047A1 (en) 1997-05-09 1998-11-12 Trustees Of The University Of Pennsylvania Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
GB9813540D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813554D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
NZ509030A (en) 1998-06-23 2003-07-25 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
GB9813535D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
CA2347512C (en) 1998-10-16 2005-12-06 Pfizer Inc. Adenine derivatives
DE69920045T2 (de) * 1998-12-31 2005-09-29 Aventis Pharmaceuticals Inc. Verfahren zur herstellung von n6-substituierten deaza-adenosinderivaten
US7427606B2 (en) * 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US6322771B1 (en) 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
US6214807B1 (en) * 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6586413B2 (en) * 1999-11-05 2003-07-01 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
GB0003960D0 (en) 2000-02-18 2000-04-12 Pfizer Ltd Purine derivatives
GB0022695D0 (en) 2000-09-15 2000-11-01 Pfizer Ltd Purine Derivatives
DE60203702T2 (de) * 2001-01-16 2006-03-02 Can-Fite Biopharma Ltd. Verwendung eines adenosin-a3-rezeptor-agonisten zur hemmung der virenreplikation
GB2372741A (en) 2001-03-03 2002-09-04 Univ Leiden C2,8-Disubstituted adenosine derivatives and their different uses
US20040162422A1 (en) * 2001-03-20 2004-08-19 Adrian Hall Chemical compounds
EP1258247A1 (en) * 2001-05-14 2002-11-20 Aventis Pharma Deutschland GmbH Adenosine analogues for the treatment of insulin resistance syndrome and diabetes
WO2003029264A2 (en) 2001-10-01 2003-04-10 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
US7414036B2 (en) * 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
DE60318192T2 (de) 2002-04-10 2008-04-30 The University Of Virginia Patent Foundation Verwendung von a2a adenosin rezeptor agonisten und anti-pathogene mittel enthaltenden kombinationen zur behandlung von entzündungskrankheiten
US7465715B2 (en) * 2003-12-29 2008-12-16 Can-Fite Biopharma, Ltd. Method for treatment of multiple sclerosis
CA2557285A1 (en) 2004-03-05 2005-09-15 Cambridge Biotechnology Limited Adenosine receptor agonists
JP2007536241A (ja) 2004-05-03 2007-12-13 ユニバーシティ オブ バージニア パテント ファウンデーション 糖尿病性腎症の処置のためのａ２ａアデノシンレセプターアゴニスト
PE20060272A1 (es) * 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
EP1781604B1 (en) * 2004-06-23 2013-08-07 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amide) salts for treatment of cancers
PL1778239T3 (pl) 2004-07-28 2014-01-31 Can Fite Biopharma Ltd Agoniści receptora adenozynowego A3 do leczenia zaburzeń suchego oka w tym zespołu Sjogrena
US7825102B2 (en) * 2004-07-28 2010-11-02 Can-Fite Biopharma Ltd. Treatment of dry eye conditions
WO2006031505A1 (en) * 2004-09-09 2006-03-23 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Purine derivatives as a3 and a1 adenosine receptor agonists
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
US20080051364A1 (en) * 2004-11-08 2008-02-28 Pninna Fishman Therapeutic Treatment of Accelerated Bone Resorption
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
ME02012B (me) * 2005-02-04 2013-02-28 Millennium Pharm Inc INHIBITORI El AKTIVIRAJUĆIH ENZIMA
GB0505219D0 (en) 2005-03-14 2005-04-20 Novartis Ag Organic compounds
GB0514809D0 (en) * 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
BRPI0619395A2 (pt) * 2005-11-30 2011-10-04 Can Fite Biopharma Ltd uso de um agonista de receptor de adenosina a3(a3ar)
CN101410114B (zh) * 2006-01-26 2012-07-04 美国政府卫生与公共服务部 A3腺苷受体别构调节剂
RS52437B (en) * 2006-02-02 2013-02-28 Millennium Pharmaceuticals Inc. ACTIVE INHIBITORS Enzyme E1
US20080027022A1 (en) * 2006-02-08 2008-01-31 Linden Joel M Method to treat gastric lesions
GB0607953D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
PL2322525T3 (pl) 2006-04-21 2014-03-31 Novartis Ag Pochodne puryny do zastosowania jako agoniści receptora adenozyny A<sub>2A</sub>
GB0607944D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607948D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607950D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607945D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607954D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607951D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
EP1889846A1 (en) 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
US8008307B2 (en) * 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
EP1903044A1 (en) * 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
KR20090087054A (ko) * 2006-11-10 2009-08-14 노파르티스 아게 시클로펜텐 디올 모노아세테이트 유도체
US20080312160A1 (en) * 2007-04-09 2008-12-18 Guerrant Richard L Method of treating enteritis, intestinal damage, and diarrhea from c. difficile with an a2a adenosine receptor agonist
US20080262001A1 (en) * 2007-04-23 2008-10-23 Adenosine Therapeutics, Llc Agonists of a2a adenosine receptors for treating recurrent tumor growth in the liver following resection
US8153781B2 (en) * 2007-06-29 2012-04-10 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Dendrimer conjugates of agonists and antagonists of the GPCR superfamily
MX2010004234A (es) * 2007-10-17 2010-04-30 Novartis Ag Derivados de purina como ligandos del receptor de adenosina a1.
US20090181934A1 (en) * 2007-10-17 2009-07-16 Novartis Ag Organic Compounds
US8183225B2 (en) * 2007-11-08 2012-05-22 New York University Inhibition of bone resorption using medical implants containing adenosine receptor antagonists
EP2240020A4 (en) * 2008-01-09 2011-05-11 Trovis Pharmaceuticals Llc INTRATHEAL TREATMENT OF NEUROPATHIC PAIN WITH A2AR AGONISTS

Also Published As

Publication number Publication date
WO2007121924A2 (en) 2007-11-01
JP2009534341A (ja) 2009-09-24
HRP20110445T1 (hr) 2011-07-31
DE602007013203D1 (de) 2011-04-28
EP2018388A2 (en) 2009-01-28
IL194398A0 (en) 2009-08-03
DK2018388T3 (da) 2011-06-27
AU2007241347A1 (en) 2007-11-01
TNSN08409A1 (en) 2010-04-14
US20100190784A1 (en) 2010-07-29
KR20080112399A (ko) 2008-12-24
MA30404B1 (fr) 2009-05-04
ATE502040T1 (de) 2011-04-15
GB0607950D0 (en) 2006-05-31
ECSP088837A (es) 2008-11-27
CR10328A (es) 2008-11-18
ZA200808103B (en) 2009-07-29
US8193164B2 (en) 2012-06-05
CL2007001132A1 (es) 2008-05-23
SI2018388T1 (sl) 2011-07-29
GT200800218A (es) 2008-12-15
CN101437829A (zh) 2009-05-20
PT2018388E (pt) 2011-06-27
AR060606A1 (es) 2008-07-02
NO20084456L (no) 2008-12-09
RU2008145715A (ru) 2010-05-27
TW200813074A (en) 2008-03-16
CN101437829B (zh) 2012-03-21
EP2018388B9 (en) 2011-10-05
MX2008013398A (es) 2008-11-04
PL2018388T3 (pl) 2011-08-31
ES2363255T3 (es) 2011-07-28
CY1111568T1 (el) 2015-10-07
EP2018388B1 (en) 2011-03-16
WO2007121924A3 (en) 2008-09-04
CA2648037A1 (en) 2007-11-01

Similar Documents

Publication Publication Date Title
PE20071228A1 (es) Compuestos derivados de purina como activadores del receptor de adenosina a2a
PE20081151A1 (es) Derivados de imidazol como activadores del receptor de adenosina a2a
PE20070848A1 (es) Derivados de pirimidina como ligandos del receptor de histamina h4
PE20110061A1 (es) Derivados de diamino-piridina, pirimidina y piridazina como moduladores del receptor h4 de histamina
PE20080361A1 (es) Compuestos derivados de purina como activadores del receptor de adenosina a2a
PA8783501A1 (es) Derivados de quinaxolina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
PE20110419A1 (es) Compuestos de pirrolo-pirimidina como inhibidores de cdk
NO20092249L (no) Polymorfer av succinatsalt av 2-[6-(3-amino-piperidin-1-yl)-3-metyl-2,4-diokso-3,4-diokso-3,4-dihydro-2H-pyrimidin-1-ylmetyl]-4-fluor-benzonitril og fremgangsmater for anvendelse derav
PE20060833A1 (es) Derivados de purina como agonistas del receptor a2a de adenosina
NO20081581L (no) Polymorfer av benzoatsalt av 2-[[6-[(3R)-3-amino-l-piperldinyl]-3,4-dihydro-3-metyl-2,4-diokso- 1(2H)-pyrlmidinylJmetyl)benzonitril, og fremgangsmater for anvendelse derav
PE20070407A1 (es) Compuestos derivados de pirazina como antagonistas del receptor a2b de adenosina
PE20121127A1 (es) Derivados de piridina y pirazina como moduladores de cinasa de proteina
PE20141203A1 (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
PE20010430A1 (es) DERIVADOS DE PURINA COMO AGONISTAS DEL RECEPTOR DE ADENOSINA A2a
PE20060556A1 (es) Derivados de urea ciclicos sustituidos con heterociclo como inhibidores de quinasa
PE20081806A1 (es) Imidazo- y triazolopirimidinas sustituidas
PE20080842A1 (es) Benzoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasas janus
PE20080944A1 (es) Derivados de pirimidina como inhibidores del receptor de cinasa activina(alk-5)
PE20090895A1 (es) Derivados de triazol como inhibidores de la jak quinasa
WO2010065898A2 (en) Egfr kinase knockdown via electrophilically enhanced inhibitors
EA201001391A1 (ru) Замещенные производные ксантинов и их применение
PE20081887A1 (es) Nuevo compuesto de adenina
PE20091035A1 (es) Derivados de 2-aminopirimidina
PE20040934A1 (es) Derivados de pirimidina como inhibidores selectivos de tirosina quinasas
ATE526328T1 (de) Als inhibitoren von proteinkinasen geeignete aminopyrimidine

Legal Events

Date Code Title Description
FC Refusal